Calliditas Therapeutics AB (publ)
SSE:CALTX.ST
107.8 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Calliditas Therapeutics AB (publ) |
Symbool | CALTX.ST |
Munteenheid | SEK |
Prijs | 107.8 |
Beurswaarde | 5,785,850,440 |
Dividendpercentage | 0% |
52-weken bereik | 80.8 - 141.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Renee Aguiar-Lucander |
Website | https://www.calliditas.se |
An error occurred while fetching data.
Over Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)